Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Thermage appoints new CFO
Mr Glenn, the former CFO of Cholestech Corporation, succeeds Laureen DeBuono, who resigned from the company after five years of service to pursue broader executive leadership opportunities in
Mr Glenn, the former CFO of Cholestech Corporation, succeeds Laureen DeBuono, who resigned from the company after five years of service to pursue broader executive leadership opportunities in
Under the terms of the agreement, ImmunoGen gains the exclusive right to develop and commercialize a TAP compound that consists of an integrin-targeting antibody developed by Centocor and
The lead candidate for HuMax-CD32b was selected from a panel of over 60 antibodies based on its excellent selectivity and binding ability for the CD32b target and potent
The trial results indicate that PRX302 is safe and well tolerated and shows very promising signs of therapeutic activity for the treatment of benign prostatic hyperplasia (BPH). Despite
Top line data show that the multi-center, double-blind, placebo-controlled study successfully met all of its co-primary endpoints and that Ophena was well tolerated. The study was conducted in
The trial results demonstrated that ACAM-FLU-A was well tolerated and capable of stimulating an immune response. Although immune responses were observed in all groups that received vaccine, the
This new Phase II clinical trial in adults with non-neurogenic over-active bladder (OAB) and urge predominant incontinence is an open-label, prospective, single-study group trial. Patients will undergo a
Proceeds from the financing will be used to accelerate the development of Tempo’s preclinical pipeline of multi-compartmental, nanoparticle-based drugs that have the potential to substantially improve the efficacy
The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition
NT-proBNP is a key cardiac marker for a broad array of cardiovascular conditions, including the diagnosis and management of heart failure, and risk stratification of patients with acute